|Articles|October 14, 2022
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells
Author(s)Univercells Technologies
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
2
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
3
Top BP Videos of 2025: An Intersection of AI, Innovation, and Compliance
4
Conjugation and Regulation Challenges for Advanced Molecules: Part Two of Three with Abzena
5